S&P Futures
5,913.00 +7.00 (+0.12%) Dow Futures
43,573.00 +55.00 (+0.13%) Nasdaq Futures
20,511.25 +27.75 (+0.14%) Russell 2000 Futures
2,296.60 +5.40 (+0.24%) Crude Oil
69.47 +0.25 (+0.36%) Gold
2,738.40 +8.40 (+0.31%)
Nanobiotix S.A. (NANO.PA)
| Previous Close | 4.4180 |
| Open | 4.4000 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 4.4000 - 4.5220 |
| 52 Week Range | 3.8160 - 7.9300 |
| Volume | |
| Avg. Volume | 47,261 |
| Market Cap | 212.373M |
| Beta (5Y Monthly) | 1.29 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.7400 |
| Earnings Date | Nov 10, 2024 - Nov 14, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.80 |
GlobeNewswireVoting Rights and Shares Capital of the Company
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Paris, France, October 11, 2024Market: Euronext Paris / NasdaqEuronext Compartment: B ISIN code: FR0011341205Nasdaq: NBTXBloomberg: NANO:FPReuters: NANO.PAWebsite: www.nanobiotix.com DateNumber of Shares OutstandingTotal number of voting rightsTotal voting rights, theoretical1
- GlobeNewswire
NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results
RT-NBTXR3 followed by anti-PD-1 demonstrated favorable safety profile, disease control and tumor response in patients both naïve and resistant to anti-PD-1, suggesting that NBTXR3 may prime the immune system before checkpoint therapySeveral clinical milestones expected over the next 12-18 months including updated data in pancreatic, and head and neck cancer, and initial data in esophageal and lung cancer€66.3 million in cash and cash equivalents as of June 30, 2024, with a cash runway extended i
